A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2144-2151

  Kim, Daejin ^a   Lee, In Hyun ^a   Kim, Sunghyun ^a   Choi, Minsuk ^a   Kim, Hyungjun ^a   Ahn, Sukyung ^a   Saw, Phei Er ^a   Jeon, Hyungsu ^a   Lee, Yumi ^a   Jon, Sangyong ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; PROTEIN BCL XL; STAT3 PROTEIN; STAT3 SPECIFIC APTIDE; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL VIABILITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899509680     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2187     Document Type: Article

References (25)

1. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
2. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
3. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56.
4. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 2009;27:4422-32.
5. Blaskovich MA, Sun JZ, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (Cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9.
6. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 2007;104:7391-6.
7. Lin L, Hutzen B, Zuo MX, Ball S, Deangelis S, Foust E, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010;70: 2445-54.
8. Xu S, Grande F, Garofalo A, Neamati N. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther 2013;12:937-49.
9. Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res 2013;73: 1922-33.
10. Zhang XL, Jian Z, Wang LH, Wei HM, Tian ZG. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. Bmc Cancer 2007;7:149.
11. Alshamsan A, Hamdy S, Samuel J, El-Kadi AOS, Lavasanifar A, Uludag H. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 2010;31:1420-8.
12. Borghouts C, Kunz C, Delis N, Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol Cancer Res 2008;6:267-81.
13. Zhao W, Jaganathan S, Turkson J. Acell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem 2010;285:35855-65.
14. Turkson J, Kim JS, Zhang SM, Yuan J, Huang M, Glenn M, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004;3:261-9.
15. Shahani VM, Yue PB, Fletcher S, Sharmeen S, Sukhai MA, Luu DP, et al. Design, synthesis and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chemi 2011;19:1823-38.
16. Xi SC, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;24:970-9.
17. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276: 45443-55.
18. Coleman DR, Ren ZY, Mandal PK, Cameron AG, Dyer GA, Muranjan S, et al. Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-Affinity peptide inhibitor. J Med Chem 2005;48:6661-70.
19. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. The interaction of specific peptide aptamers with the DNA-binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2004;2:170-82.
20. Timofeeva OA, Gaponenko V, Lockett SJ, Tarasov SG, Jiang S, Michejda CJ, et al. Rationally designed inhibitors identify STAT3 Ndomain as a promising anticancer drug target. Acs Chem Biol 2007; 2:799-809.
21. Debnath B, Xu SL, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J Med Chem 2012;55:6645-68.
22. Kim S, Kim D, Jung HH, Lee IH, Kim JI, Suh JY, et al. Bio-inspired design and potential biomedical applications of a novel class of highaffinity peptides. Angew Chem-Int Ed 2012;51:1890-4.
23. Zhang X, Zhang J, Wang L, Wei H, Tian Z. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;7:149.
24. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, et al. Arginine-rich peptides - An abundant source ofmembrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;276:5836-40.
25. Lee IH, Park YT, Roh K, Chung H, Kwon IC, Jeong SY. Stable paclitaxel formulations in oily contrast medium. J Control Release 2005;102: 415-25.